Physician profile
Daniel C Goodman
NPI 1780678896
$3,030.10
in general payments reported to CMS, 2019-2025
26 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $146 · 2021: $287 · 2022: $716 · 2023: $812 · 2024: $520 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $441.41 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $405.39 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $324.12 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $232.00 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $224.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.97 | 2021-2025 | |
| Abbott Laboratories | $171.27 | 2022-2023 | Freestyle Libre 3 |
| Procept Biorobotics Corporation | $121.43 | 2024 | Aquabeam System |
| Amgen INC. | $120.04 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $100.17 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $95.82 | 2021-2024 | |
| Seqirus USA INC | $80.68 | 2022-2025 | Flucelvax, Fluad |
| Mylan Specialty L.P. | $66.60 | 2023-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $64.84 | 2022-2023 | Jynarque, Rexulti |
| Astellas Pharma US INC | $60.17 | 2022-2023 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $47.67 | 2019-2022 | |
| Dexcom, INC. | $36.81 | 2022-2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $35.44 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $32.05 | 2022-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $30.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.02 | 2022 | |
| Ibsa Pharma INC. | $22.55 | 2024 | Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $18.93 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.